



Antifungal Activity of Some Benzimidazole-Hydrazones

Ulviye ACAR ÇEVİK^{1,2} , Derya OSMANİYE^{1,2*} 

¹ Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey
² Doping and Narcotic Compounds Analysis Laboratory, Faculty of Pharmacy, Anadolu University, Eskişehir, Turkey

Received: 19.06.2019; Accepted: 19.09.2019

<http://dx.doi.org/10.17776/cs.j.579734>

Abstract. In the present work, 15 4-(1-(prop-2-in-1-yl)-1H-benzimidazole-2-yl)-N'-(substitutedmethylene)benzohydrazide derivatives (**4a-4o**) were re-synthesized to evaluate their antifungal activity. Structure identification of synthesized compounds was elucidated by ¹H-NMR, ¹³C-NMR, and HRMS spectroscopic methods. Inhibitory potential of the re-synthesized compounds was investigated against *Candida supp.* The compounds **4e** and **4l** showed significant anti fungal activity. Consistent with the activity studies, **4e** was found to be potent derivative with its MIC₅₀ value of (1.95 µg/mL) against *Candida glabrata*. And **4l** was found to be potent derivative with its MIC₅₀ value of (1.95 µg/mL) against *Candida krusei*.

Keywords: Benzimidazole, Hydrazone, Antifungal activity, NMR, HRMS

Bazı Benzimidazol-Hidrazonların Antifungal Etkinliği

Özet. Mevcut çalışmada, 15 4-(1-(prop-2-in-1-il)-1H-benzimidazol-2-il)-N'-(süstitüemetilen) benzohidrazit türevleri (**4a-4o**), antifungal aktivitelerini değerlendirmek üzere yeniden sentezlendi. Sentezlenen bileşiklerin yapı tanımlamaları ¹H-NMR, ¹³C-NMR ve HRMS spektroskopik yöntemlerle açıklandı. Yeniden sentezlenen bileşiklerin antifungal etkinlikleri *Candida* türlerine karşı değerlendirildi. Bileşik **4e** ve **4l** önemli aktivite gösterdi. Aktivite çalışmaları ile uyumlu olarak, **4e** bileşiği *Candida glabrata*'ya karşı 1.95 µg / mL MIC₅₀ değeri ile güçlü bir türev olarak bulundu. Aynı zamanda **4l** bileşiği *Candida krusei*'ye karşı 1.95 µg / mL MIC₅₀ değeri ile güçlü bir türev olarak bulundu.

Anahtar Kelimeler: Benzimidazol, Hidrazon, Antifungal aktivite, NMR, HRMS

1. INTRODUCTION

Life loss depending on fungal infections are more than 1.35 million per year worldwide [1]. *Aspergillus spp.*, *Cryptococcus neoformans* and *Candida spp.* are still the three main pathogens of fungal infections. Over the last few decades, the occurrence of systemic fungal infections has increased considerably in immunocompromised hosts, particularly patients who receive cancer chemotherapy or patients with AIDS and undergone organ transplantation [1-3]. Some research teams stated that *Candida albicans* (*C. albicans*) which caused severe mucosal infections

with potentially fatal invasive infections was the most common fungus in these patients [4, 5]. On the other hand, only a restricted number of antifungal agents are formerly accessible to treat these life-threatening fungal infections [6]. Presently, clinical antifungal agents can be separated into four classes: Echinocandins (such as Micafungin and Caspofungin), antimetabolites (such as 5-fluorocytosine) polyenes (such as Nystatin and Amphotericin B) and azoles (such as Itraconazole and Fluconazole) [2,3].

* Corresponding author. Email address: dosmaniye@anadolu.edu.tr
<http://dergipark.gov.tr/cs.j> ©2016 Faculty of Science, Sivas Cumhuriyet University

Azoles inhibits lanosterol 14- α -demethylase enzyme; which is responsible for converting lanosterol into ergosterol. Ergosterol is the major component of fungal cytoplasmic membranes and responsible for bioregulation of membrane asymmetry [7]. Azoles are first-line drug for fungal infections due to their wide antifungal spectrum, high potency and low toxicity [8]. However, some problems remain, such as severe drug resistance, cytotoxicity. However, emergence of drug resistance, environmental hazards and other problems objectively indicate the urgent need for novel antifungal agents [2,9].

Nitrogen heterocycles are common structural motifs in compounds with antifungal activity [4]. Benzimidazole that was an important heterocyclic nucleus that has been used extensively in medicinal chemistry is a component of vitamin B12 and is related to the DNA base purine and the stimulant caffeine. Substituted benzimidazole displays a broad spectrum of potential pharmacological activities such as anti-inflammatory, anti-tubercular, anticancer, antibacterial, antiviral and antifungal activity. [5-7, 9, 10-17]. In addition to benzimidazole derivatives, hydrazone based compounds, which bear an azomethine -NHN=CH- functional group, have showed antifungal activity [18,19].

Based on the above information, antifungal activities of the compounds containing benzimidazole and hydrazone residues were the subject of curiosity. For this purpose, we resynthesized some benzimidazole-hydrazone based upon the studies that reported the antifungal potentials [20].

2. MATERIALS AND METHODS

2.1. Chemistry

All chemicals used in the syntheses were purchased either from Sigma-Aldrich Chemicals (Sigma-Aldrich Corp., St. Louis, MO, USA) or Merck Chemicals (Merck KGaA, Darmstadt, Germany). Melting points of the obtained compounds were determined by MP90 digital melting point apparatus (Mettler Toledo, OH, USA) and were uncorrected. The IR spectra were obtained on a Shimadzu, IR Prestige-21 (Shimadzu, Tokyo, Japan). ^1H NMR and ^{13}C

NMR spectra of the synthesized compounds were registered by a Bruker 300 MHz and 75 MHz digital FT-NMR spectrometer (Bruker Bioscience, Billerica, MA, USA) in $\text{DMSO-}d_6$, respectively. Splitting patterns were designated as follows: s: singlet; d: doublet; t: triplet; m: multiplet in the NMR spectra. Coupling constants (J) were reported as Hertz. M+1 peaks were determined by Shimadzu LC/MS ITTOF system (Shimadzu, Tokyo, Japan). All reactions were monitored by thin-layer chromatography (TLC) using Silica Gel 60 F254 TLC plates (Merck KGaA, Darmstadt, Germany).

2.1.1. General procedure for the synthesis of target compounds (4a-4o)

In order to determine the antifungal activity, synthesis studies were carried out for compound 4a-4o. Synthesis studies was performed by means of previous study reported by our research group [20].

2.2. Antifungal Activity

The *in vitro* antifungal activities of all resynthesized derivatives 4a-4o were screened at between 1 mg/mL-1.95 $\mu\text{g/mL}$ concentrations using various *Candida* strains including *C. albicans* (ATCC 90030), *C. glabrata* (ATCC 90030) *C. krusei* (ATCC 6258) and *C. parapsilopsis* (ATCC 22019) and following the protocol of the EUCAST in keeping with the previous studies reported by our research group [21, 22].


3. RESULTS AND DISCUSSIONS

3.1. Chemistry

The compounds 4a-4o were re-synthesized as summarized in Scheme 1. Compound 1 was synthesized under microwave irradiation using 1,2-phenylenediamine and methyl 4-formylbenzoate. Reaction of Methyl 4-(1*H*-benzo[d]imidazol-2-yl)benzoate and propargyl bromide gave the compound 2. Reaction of the methyl 4-(1-(prop-2-in-1-yl)-1*H*-benzo[d]imidazole-2-yl)benzoate (2) and hydrazine hydrate gave 4-(1-(prop-2-in-1-yl)-1*H*-benzo[d]imidazole-2-yl)benzohydrazide (3). Reaction of compound 3 and aldehydes afforded to the target compounds (4a-4o).

Structural elucidation of the synthesized compounds (**4a-4o**) was carried out by spectral analyses including IR, ¹H-NMR, ¹³C-NMR and

HRMS. All the results of the analysis are in accordance with our previous report [20].



Comp.	Ar	Comp.	Ar
4a	Thiophen-2-yl	4i	4-Methoxyphenyl
4b	5-Nitro-thiophen-2-yl	4j	2-Methoxyphenyl
4c	Pyrrol-2-yl	4k	3-Methoxyphenyl
4d	1-Methyl-pyrrol-2-yl	4l	3-Hydroxyphenyl
4e	Pyridin-3-yl	4m	3,5-Dihydroxyphenyl
4f	4-Fluorophenyl	4n	3,5-Dimethoxyphenyl
4g	4-Chlorophenyl	4o	2,3-Dimethoxyphenyl
4h	4-Hydroxyphenyl		

Scheme 1: Synthesis way of the compounds **4a-4o**. **Reagents and Conditions:** **a:** Na₂S₂O₅/DMF, Microwave irradiation, 240 °C, 10 bar, 5 + 5 min. **b:** NaH/DMF, propargyl bromide, r.t, 20 h. **c:** NH₂NH₂.H₂O (%100), Microwave irradiation, 150°C, 10 bar, 10 min. **d:** EtOH/CH₃COOH, reflux, 2 h.

Table 1. MIC₅₀ (µg/mL) values of compounds **4a-4o**.

Comp.	<i>C. albicans</i>	<i>C. glabrata</i>	<i>C. krusei</i>	<i>C. parapsilosis</i>
4a	>1000	>1000	62.50	>1000
4b	>1000	>1000	>1000	>1000
4c	>1000	>1000	62.50	>1000
4d	1.95	>1000	>1000	>1000
4e	125	1.95	>1000	>1000
4f	>1000	>1000	>1000	>1000
4g	>1000	>1000	>1000	>1000
4h	1.95	>1000	>1000	15.63
4i	>1000	>1000	>1000	>1000
4j	1.95	>1000	>1000	>1000
4k	>1000	>1000	>1000	>1000
4l	15.63	>1000	1.95	>1000
4m	>1000	125	7.81	>1000
4n	>1000	>1000	>1000	>1000
4o	>1000	>1000	31.25	>1000
Ketoconazole	0.98	1.95	1.95	1.95
Fluconazole	0.98	1.95	1.95	0.98

3.2. Antifungal Activity

According to the protocol of the EUCAST reported previously by our research group [21, 22], all obtained compounds **4a-4o** were screened for their *in vitro* antifungal activity against four pathogenic fungi;

C. albicans (ATCC 90030), *C. glabrata* (ATCC 2001), *C. krusei* (ATCC 6258), *C. parapsilosis* (ATCC 22019). Ketoconazole and fluconazole were used as reference drugs. The results of antifungal activities are listed in **Table-1**. Compounds **4d**, **4h** and **4j** were determined to have MIC₅₀ values of 1.95 µg/ml against *C. albicans*. On the other hand, Compounds **4e** and

4l were determined to have MIC₅₀ values of 1.95 µg/ml against *C. glabrata* and *C. krusei*, respectively. This MIC₅₀ values is the same as the MIC₅₀ values of reference drugs against *C. glabrata* and *C. krusei*. Compound **4e** bearing pyridin-3-yl possessed good activity against *C. glabrata* with an MIC value of 1.95 µg/mL. Compound **4l** including 3-hydroxyphenyl possessed good activity against *C. krusei* with an MIC value of 1.95 µg/mL. However compound **4m** bearing 3,5-dihydroxyphenyl had weak antifungal activity. This information suggests that the hydroxy group brought to the fifth position of phenyl ring reduces the antifungal activity. The lack of activity of the methoxy-containing derivative in the third position of phenyl (**4k**) indicates that the replacement of the hydrogen and methyl group of the hydroxyl group decreases the activity. This information suggests that hydroxyl hydrogen in the third position of phenyl ring enhances activity probably by making hydrogen bonds.

4. CONCLUSION

In summary, a series of benzimidazole-hydrazone derivatives were re-synthesized and evaluated for their antifungal activity. The primary results indicated that obtained compounds **4a–4o** displayed antifungal activities within different ranges. Compounds **4e** and **4l** displayed significant activity against *C. glabrata* and *C. krusei*, respectively. Compound **4e** bearing pyridine-3-yl and compound **4l** bearing 3-hydroxyphenyl came to the fore in the series. We assume that the aromatic ring bound to the hydrazone group contributes to the antifungal activity by means of long-pair electron in third position. However, if the hydroxyl group at position third of phenyl ring is replaced by a methoxy group, the activity decreases activity. This information suggests that the steric hindrance of the methyl group abolishes the effect of the long-pair electron, or that the hydroxyl hydrogen's ability to form hydrogen bonds contributes to activity.

REFERENCES

- [1] Wang S.Q., Wang Y.F., Xu Z., Tetrazole hybrids and their antifungal activities, Eur. J. Med. Chem., 170 (2019) 225-234.
- [2] Zhao L., Tian L., Sun N., Chen Y., Wang X., Zhao S., Su X., Zhao D., Cheng M., Design, synthesis, and structure-activity relationship studies of 1-amino alcohol derivatives as broad-spectrum antifungal agents, Eur. J. Med. Chem., 177 (2019) 374-385.
- [3] Zhao S., Zhang X., Wei P., Su X., Zhao L., Wu M., Hao C., Liu C., Zhao D., Cheng M., Design, synthesis and evaluation of aromatic heterocyclic derivatives as potent antifungal agents. Eur. J. Med. Chem., 137 (2017) 96-107.
- [4] Lino C.I., de Souza I.G., Borelli B.M., Silverio Matos T.T., Santos Teixeira I.N., Ramos J.P., de Souza Fagundes E.M., de Oliveira Fernandes P., Maltarollo V.G., Johann S., de Oliveira R.B., Synthesis, molecular modeling studies and evaluation of antifungal activity of a novel series of thiazole derivatives, Eur. J. Med. Chem., 151 (2018) 248-260.
- [5] Shi Y., Jiang K., Zheng R., Fu J., Yan L., Gu Q., Zhang Y., Lin F., Design, Microwave-Assisted Synthesis and in Vitro Antibacterial and Antifungal Activity of 2,5-Disubstituted Benzimidazole, Chem. Biodiversity, 16 (2016) 1800510.
- [6] Villa P., Arumugam N., Almansour A.I., Kumar R.S., Mahalingam S.M., Maruoka K., Thangamani S., Benzimidazole tethered pyrrolo[3,4-b]quinoline with broad-spectrum activity against fungal pathogens, Bioorg. Med. Chem. Lett., 29 (2019) 729-733.
- [7] Karaburun A.C., Kaya Çavuşoğlu B., Acar Çevik U., Osmaniye D., Sağlık B.N., Levent S., Özkay Y., Atlı Ö., Koparal A.S., Kaplancıklı Z.A., Synthesis and Antifungal Potential of Some Novel Benzimidazole-1,3,4-Oxadiazole Compounds, Molecules, 24 (2019) 191.
- [8] Wu J., Ni T., Chai X., Wang T., Wang H., Chen J., Jin Y., Zhang D., Yu S., Jiang Y., Molecular docking, design, synthesis and antifungal activity study of novel triazole derivatives, Eur. J. Med. Chem., 143 (2018) 1840-1846.
- [9] Si W.J., Wang X.B., Chen M., Wang M.Q., Lu A.M., Yang C.L., Design, synthesis, antifungal

- activity and 3D-QSAR study of novel pyrazole carboxamide and niacinamide derivatives containing benzimidazole moiety, *New. J. Chem.*, 43 (2019) 3000.
- [10] Kashid B.B., Ghanwat A.A., Khedkar V.M., Dongare B.B., Shaikh M.H., Deshpande P.P., Wakchaure Y.B., Design, Synthesis, In Vitro Antimicrobial, Antioxidant Evaluation, and Molecular Docking Study of Novel Benzimidazole and Benzoxazole Derivatives, *J. Heterocycle. Chem.*, 56 (2019) 895.
- [11] Yadav S., Lim S.M., Ramasamy K., Vasudevan M., Ali Shah S.A., Mathur A., Narasimhan B., Synthesis and evaluation of antimicrobial, antitubercular and anticancer activities of 2-(1-benzoyl-1H-benzo[d]imidazol-2-ylthio)-N-substituted acetamides, *Chemistry Central Journal*, 12-66 (2018) 1-14.
- [12] Abdel-Wahab S.M., Abdelsamii Z.K., Abdel-Fattah H.A., El-Etrawy A.S., Dawe L.N., Swaroop T.R., Georghiou P.E., Synthesis of 2-Aryl- and 2-Haloarylbenzimidazole-N1-acetamido Conjugates and a Preliminary Evaluation of Their Antifungal Properties, *ChemistrySelect*, 3 (2018) 8106-8110.
- [13] Chandrika N.T., Shrestha S.K., Ngo H.X., Tsodikov O.V., Howard K.C., Garneau-Tsodikova S., Alkylated Piperazines and Piperazine-Azole Hybrids as Antifungal Agents, *J. Med. Chem.*, 61 (2018) 158-173.
- [14] Vijey Aanandhu M., Anbhule Sachin J., Synthesis, Characterization, And Evaluation Of Antifungal Properties Of Substituted Benzimidazole Analog, *Asian J. Pharm. Clin. Res.*, 11 (2018) 66-69.
- [15] Li L.X., Jiao J., Wang X.B., Chen M., Fu X.C., Si W.J., Yang C.L., Synthesis, Characterization, and Antifungal Activity of Novel Benzo[4,5]imidazo[1,2-d][1,2,4]triazine Derivatives, *Molecules*, 23 (2018) 746.
- [16] Eren B., Yılmaz Ö., Çetin G., Darcan C., Microwave Assisted Synthesis and Potent Antimicrobial Activity of Some Novel 1,3-Dialkyl-2-arylbenzimidazolium Salts, *Lett. Drug. Des. Discov.*, 15 (2018) 621-633.
- [17] Liu H.B., Gao W.W., Tanganchu V.K.R., Zhou C.H., Geng R.X., Novel aminopyrimidinyl benzimidazoles as potentially antimicrobial agents: Design, synthesis and biological evaluation, *Eur. J. Med. Chem.*, 143 (2018) 66-84.
- [18] Özkay Y., Tunalı Y., Karaca H., Işıklıdağ İ., Antimicrobial activity and a SAR study of some novel benzimidazole derivatives bearing hydrazone moiety, *Eur. J. Med. Chem.*, 45 (2010) 3293-3298.
- [19] Küçükgülzel S.G., Mazi A., Sahin F., Öztürk S., Stables J., Synthesis and biological activities of diflunisal hydrazide/hydrazones, *Eur. J. Med. Chem.*, 38 (2003) 1005-1013.
- [20] Can Ö.D., Osmaniye D., Demir Özkay U., Sağlık B.N., Levent S., İlgin S., Baysal M., Özkay Y., Kaplacıklı Z.A., MAO enzymes inhibitory activity of new benzimidazole derivatives including hydrazone and propargyl side chains, *Eur. J. Med. Chem.*, 131 (2017) 92-106.
- [21] Rodriguez-Tudela J.L., Barchiesi F. Subcommittee on Antifungal Susceptibility Testing (AFST). EUCAST Definitive Document EDef 7.1: Method for the determination of broth dilution MICs of antifungal agents for fermentative yeast. *Clin. Microbiol. Infect.*, 14 (2008) 398-405.
- [22] Can N.Ö., Çevik U.A., Sağlık B.N., Özkay Y., Atlı Ö., Baysal M., Özkay Ü.D., Can Ö.D., Pharmacological and Toxicological Screening of Novel Benzimidazole-Morpholine Derivatives as Dual-Acting Inhibitors, *Molecules*, 22 (2017) 1374.